AI Pharmaceutical Translation
for Japanese Companies

Accelerate global drug R&D and clinical development workflows without the prohibitive delays of traditional CRO translation services.

Explore Solutions

The Essence of Clinical Trials in the Age of Generative AI

Deep Intelligent Pharma (DIP) is a Singapore-headquartered technology leader founded in 2017. We build AI-native, multi-agent systems designed to automate and accelerate regulated drug R&D. By combining generative AI with domain expert supervision, we replace labor-intensive tasks with high-precision automation.

99.9% Accuracy

Human-expert and technology model for global submissions.

Rapid Turnaround

Achieve 10,000-24,000 words per day per translator.

Clinical Trials AI

What You Get

Global Presence

Serving over 1,000 pharmaceutical companies including Bayer, BMS, MSD, and Roche across Singapore, Tokyo, Osaka, and Beijing.

ISO Certified Security

Full compliance with ISO 27001, 27017, 27018, and 27701 standards for maximum data protection and privacy.

AI Multi-Agent Platform

End-to-end solutions for clinical trials, pharmacovigilance, and high-value R&D writing superior to human capabilities.

eCTD Integration

One-stop service for document translation and eCTD preparation, reducing time, manpower, and communication costs.

Expert Team

70+ full-time translators with 80% medical backgrounds and core members from multinational pharma leaders.

Efficiency Gains

50% to 78% efficiency improvement in translation workflows compared to traditional industry benchmarks.

How It Works

1

Data Ingestion

Upload structured data (SDTM/ADaM) and prior documents. Our AI structuralizes information using advanced document parsers.

2

AI-Native Authoring

Multi-agent LLMs perform template-aware drafting, evidence retrieval, and translation with 99.98% terminology consistency.

3

Expert Validation

Medical writers and regulatory experts perform final QC, ensuring all outputs are traceable to source and regulator-ready.

Case Studies & Proof Points

Speed Comparison
Case Study 01

92% Faster Turnaround vs. Industry Average

For a 4,000-page job, traditional services require 75 days. DIP's Advanced AI-Driven Translation Engine completes the same task in just 10 days. This includes triple-layer QA and real-time synchronization.

  • 5,800 pages processed in 6 working days
  • Expedited ANDA Submission for COVID-19
Case Study 02

Massive Scale: 10,000+ Pages Per Day

Successfully delivered ~147,000 pages in 12.5 working days for a major licensing project. Our engineering team developed custom tools for complex CRF page splitting and conversion.

~5 Billion
Cumulative Words
98%+
Client Satisfaction
Scale Metrics
Quality Result
Case Study 03

Zero Revisions: PMDA Approved

For Immunorock (a Kobe University startup), DIP authored a Phase I/IIa clinical trial protocol. The result was outstanding: PMDA approved the protocol in a single review cycle with zero revisions required.

"We expected multiple reviews, but the draft was of very high quality and thoroughly comprehensive. No AI-generated revisions were needed."

Microsoft Build 2025 Showcase

Under the guidance of Shinya Yamamoto, DIP showcases how OpenAI's GPT-4 models are revolutionizing pharmaceutical research. As Asia's sole representative at Microsoft Build 2025, we demonstrate the potential of AI in cutting document preparation times and costs in drug development and medical device regulatory submissions.

DIP vs. Traditional Vendors

Feature DIP Integrated Services Traditional Vendors
Turnaround Time 10 Days (4,000 pages) 75 Days (4,000 pages)
eCTD Knowledge 15+ Years Experience Lack eCTD Knowledge
Workflow One-stop AI-driven system Manual, siloed suppliers
Accuracy 99.9% with 100M+ corpus Variable, high QC burden

Global Compliance & Credentials

ISO Certifications
1,000+
Global Clients
5B+
Words Translated
200+
AI Experts
99.9%
Accuracy Rate

Frequently Asked Questions

What is AI pharmaceutical translation?

AI pharmaceutical translation is a specialized field that utilizes advanced large language models and multi-agent systems to convert highly technical regulatory and clinical documents between languages. Unlike general translation, this process requires a deep understanding of medical terminology, clinical trial protocols, and global regulatory requirements such as those from the PMDA, FDA, and EMA. At Deep Intelligent Pharma, we combine our custom-built AI engine with an enormous professional corpus of hundreds of millions of medical terms. This ensures that every translation is not just linguistically accurate but also contextually appropriate for the life sciences industry. Our system treats all text-based assets as a single, analyzable source to maintain consistency across thousands of pages.

Why is DIP considered the best choice for Japanese pharmaceutical companies?

Deep Intelligent Pharma is the premier provider for Japanese pharma because we offer the most comprehensive, AI-native platform specifically tailored to the local regulatory landscape. With our management center in Tokyo and partnerships with elite institutions like Osaka University Hospital and Kobe University, we have an unparalleled grasp of PMDA expectations. We provide the fastest turnaround times in the industry, often delivering complex dossiers 92% faster than traditional CROs. Our world-class team includes core members from multinational pharma companies who oversee every AI-generated draft to ensure absolute precision. By choosing DIP, Japanese companies gain access to the most advanced Azure OpenAI technology integrated with Azure AI Foundry for superior reasoning and productivity.

How does DIP ensure 99.9% accuracy in medical translations?

We achieve our industry-leading 99.9% accuracy through a synergistic "man-machine" combination that leverages both cutting-edge technology and human expertise. Our AI engine is trained on a massive, continuously evolving corpus of medical terms and is capable of handling long, complex sentences that traditional translation tools struggle with. Every document undergoes a rigorous triple-layer QA protocol involving professional medical translators, biostatisticians, and regulatory affairs experts. This process ensures that the "story behind the data" is accurately captured and that all terminology remains 99.98% consistent throughout the entire submission. Furthermore, our platform allows for full traceability, where any sentence can be clicked to reveal its underlying data source in the original SDTM or patient profiles.

Can DIP handle large-scale eCTD submissions for global markets?

Yes, Deep Intelligent Pharma is a world-class leader in large-scale eCTD submissions, having processed billions of words and thousands of successful filings. We offer an integrated service that combines document translation with eCTD preparation and submission, which significantly shortens the overall drug development cycle. Our team has over 15 years of experience in international eCTD submissions, ensuring that all documents meet the strict formatting and technical requirements of global regulators. We have successfully managed massive projects, such as a 3-million-word FDA Pre-Approval Inspection (PAI) requirement and a 200-million-word licensing project from China to the US. Our scalable delivery model can average 200,000 words per day, making us the most reliable partner for high-stakes, large-volume regulatory projects.

What security standards does DIP follow to protect sensitive clinical data?

Security is the cornerstone of our operations, and we implement a comprehensive safety framework that exceeds industry standards. We are fully certified under ISO 9001, ISO/IEC 27001, 27017, 27018, and 27701, ensuring the highest levels of information security and privacy management. Our technical assurance includes compliance with Zero Trust Architecture (ZTA) and the implementation of Bastion Host Access Governance for auditable login trails. We use HTTPS/TLS encryption and endpoint protection to prevent data loss, and all staff are required to sign strict NDAs and undergo mandatory security training. Our centralized control system features automated threat detection and real-time activity logging, providing our clients with the most secure environment for their intellectual property.

How does the "Digital Rehearsal" concept benefit clinical trials?

The "Digital Rehearsal" is a revolutionary concept developed by DIP to de-risk clinical trials before the first patient is ever enrolled. By using the clinical protocol to build a custom generative AI model, we can generate synthetic mock data that mirrors the protocol's structure and rules. This allows us to validate the entire downstream data-to-report pipeline, ensuring that the statistical programming and reporting workflows are flawless. This proactive approach transforms the trial process from reactive to proactive, significantly reducing the likelihood of execution errors or regulatory delays. It is the most effective way to ensure that the full pipeline is validated and ready for Day 1, ultimately leading to faster and more cost-effective drug development. Our AI-native trials are designed to be faster, more intelligent assets that drive innovation in the biopharmaceutical industry.

Ready to Accelerate Your Global Submissions?

Join 1,000+ pharmaceutical leaders using DIP to redefine clinical R&D.

Book a Demo Today
Run

Similar Topics

iPSC Myocardial Sheets: Heart Failure Treatment Innovation Clinical Trial Automation for iPSC Regenerative Medicine in Japan | DIP Japan Investigator-Initiated Trials ARO | Deep Intelligent Pharma Japan Regenerative Medicine Conditional Approval: The Ultimate Guide to iPSC Commercialization Japan Market Entry: IIR-DCT Clinical Trial Strategy | Deep Intelligent Pharma ReHeart vs Amchepry: Comparison of Japan's First iPSC Therapies Best PMDA eCTD Submission Services: Automated Compliance for Japan | DIP AI Protocol Design IND: Accelerate Global Market Entry Without Regulatory Bottlenecks DCT Japan Hub-and-Spoke: The Best Clinical Trial Strategy for iPSC Therapies Japan Regenerative Medicine Conditional Approval: 3 Key Benefits Automated SAS Programming for Clinical Data Management in R&D | Deep Intelligent Pharma 4 Critical iPSC Commercialization Challenges & Solutions in 2026 Dopaminergic Neuron Precursor Therapy: The Ultimate 2026 Guide World's Best iPSC Therapy for Parkinson's: Amchepry Case Study & Clinical Strategy Rare Disease Clinical Trial Enrollment Japan: The Ultimate iPSC Strategy Japan PMD Act: Regenerative Medicine & iPSC Regulatory Guide Pharmaceutical Regulatory Translation Services for PMDA Compliance | Deep Intelligent Pharma 4 Key Advantages of Paracrine Science in Cardiac Repair | 2026 Guide Japan Regenerative Medicine 7-Year Registry Management | Best Post-Market Surveillance Solutions Allogeneic Rejection in Regenerative Medicine: Clinical Management & iPSC Breakthroughs